Reduced Tearing With Stable Quality of Life After Vidian Neurectomy: A Prospective Controlled Trial

xlomafota13 shared this article with you from Inoreader Reduced Tearing With Stable Quality of Life After Vidian Neurectomy: A Prospective Controlled Trial Via The Laryngoscope Objectives/Hypothesis Although vidian neurectomy (VN) is associated with decreased lacrimation, its impact on dry eye quality‐of‐life is not well‐defined. Endoscopic endonasal transpterygoid approaches (EETA) may require vidian nerve sacrifice. Study Design A prospective cohort trial. Methods A prospective trial evaluating VN during EETA on lacrimation by phenol red thread testing and dry eye severity by the five‐item Dry Eye Questionnaire (DEQ‐5) was performed. Preservation of the contralateral vidian nerve allowed comparison between the eye subjected to VN and the control eye postoperatively. Results Twenty‐one subjects were enrolled with no preoperative difference in lacrimation between eyes (P = .617) and overall mild dry eye severity. Although the control eye had no difference in lacrimation pre‐ and postoperatively, decreased tearing was noted in the VN eye at 1 month (20.8 mm vs. 15.8 mm, P = .015) and at 3 months (23.2 mm vs. 15.8 mm, P = .0051) postoperatively. Overall, no difference was noted in the DEQ‐5 score for dry eye severity between the pre‐ and postoperative measures. However, six patients were noted to have moderate to severe dry eye severity postoperatively and five of these six had decreased lacrimation (<20 mm) preoperatively. Patients with decreased tearing preoperatively demonstrated significantly worse postoperative DEQ‐5 scores when compared to patients with normal tearing (P < .0056). Conclusions VN during EETA results in decreased tearing but is not associated with increased dry eye severity overall. However, patients with decreased tearing preoperatively are at risk for increased dry eye severity and should be counseled for this risk. Level of Evidence 2 Laryngoscope, 2020 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.